Phlox Therapeutics raised €1.9M in a seed funding round led by ROM Utrecht Region to advance its RNA therapies for genetic laminopathies.
Phlox Therapeutics raised €1.9M in a seed funding round led by ROM Utrecht Region to advance its RNA therapies for genetic laminopathies.
11/13/24, 10:49 AM
Location
naardenMoney raised
€1.9 million
Industry
genetics
therapeutics
biotechnology
health care
Round Type
seed
Investors
Hubrecht Institute, Dutch Research Council (Nwo), Utrecht Health Seed Fund (Uhsf), Amsterdam Umc Venture Holding, First Fund (Managed By Bgv), Rom Utrecht Region
Naarden-based Phlox Therapeutics has raised €1.9M in funding to advance its RNA therapies for genetic laminopathies. The funding round includes ROM Utrecht Region and other existing investors, with additional non-dilutive investment from the Dutch Research Council.
Company Info
Location
naarden, north holland, netherlands
Additional Info
Phlox Therapeutics is a biotechnology company founded in 2022 that specializes in developing RNA-based gene therapies to treat genetic laminopathies and cardiomyopathies. The company focuses on targeting genetic mutations associated with these conditions, aiming to improve patient outcomes. By advancing its RNA technology, Phlox aims to become a key player in next-generation RNA therapies for genetic heart diseases. Their work seeks to address currently untreatable genetic conditions and improve treatment options for patients.